Top 10 Patient Questions

I understand why this is the question you want answered first. Unfortunately, breast imaging alone usually cannot say with 100% certainty whether something is cancer. Imaging helps estimate how concerning something looks and what should happen next. In general, the only way to know for sure is for a pathologist to examine tissue from the area through a biopsy — but most imaging findings do not need biopsy, and many biopsies do not show cancer.

Breast density refers to the proportion of fibroglandular tissue (glands and connective tissue) compared to fatty tissue on a mammogram. Dense breasts have more fibroglandular tissue and are extremely common — roughly 40–50% of women have heterogeneously or extremely dense breasts.

Dense tissue has two important implications. First, it can partially obscure small masses on a mammogram because both dense tissue and tumors appear white on the image. Second, dense breasts carry a modestly elevated independent risk for breast cancer. Many states now require that patients be notified if their breasts are dense, and supplemental screening with ultrasound or MRI may be recommended.

A callback (also called a recall) after a screening mammogram is very common and is usually not cause for alarm. Approximately 10–12% of women are called back after their first mammogram, and roughly 5–10% after subsequent screenings. The large majority of callbacks result in a normal outcome.

A callback means the radiologist saw something that needs a closer look — often an asymmetry, a possible mass, or calcifications that are easier to see with additional views or ultrasound. A BI-RADS 0 is assigned, which means the study is incomplete pending further imaging. This is a diagnostic process, not a diagnosis of cancer.

Calcifications are tiny calcium deposits in breast tissue that show up as bright white specks or clusters on a mammogram. They are extremely common and the majority are completely benign — caused by aging, past injury, or normal cellular activity.

What matters to a radiologist is the size, shape, and distribution of the calcifications. Large, round, smooth calcifications are almost always benign. Small, irregular, or tightly clustered (especially in a line) calcifications may require biopsy because they can occasionally be associated with early breast cancer or a precancerous condition called DCIS. Your radiologist will assign a BI-RADS score based on this assessment.

A cyst is a fluid-filled sac. On ultrasound, a simple cyst has a distinctive appearance — thin walls, no internal debris, and acoustic enhancement behind it — that allows a radiologist to diagnose it with certainty and classify it as BI-RADS 2 (benign). Simple cysts do not require biopsy or any treatment unless they cause discomfort.

A tumor is a solid mass. Not all solid masses are cancerous — benign tumors like fibroadenomas are very common, especially in younger women. The imaging characteristics of a solid mass (shape, margins, orientation) help the radiologist determine whether it is likely benign or suspicious, and the BI-RADS category guides next steps.

BI-RADS 4 means a finding looks suspicious enough that a biopsy is usually recommended. It does not mean you definitely have breast cancer. It means imaging cannot confidently call the area benign, so tissue sampling is recommended to get a clear answer. BI-RADS 4 covers a wide range of concern, from low suspicion to higher suspicion.

A breast biopsy is a procedure in which a small sample of tissue is removed from the suspicious area and examined by a pathologist under a microscope. It is the only way to know definitively whether a finding is benign or malignant. Being recommended for biopsy does not mean you have cancer — the majority of biopsied lesions turn out to be benign.

Most breast biopsies today are performed as minimally invasive image-guided procedures using a hollow needle — either ultrasound-guided or stereotactic (X-ray-guided). The procedure is done under local anesthesia, takes about 30–60 minutes, and does not require surgery. A small clip is typically placed at the biopsy site as a marker. Results are usually available within 2–3 business days.

Breast pain (mastalgia) is one of the most common breast complaints and is rarely caused by cancer. The vast majority of breast pain is either cyclical (related to hormonal changes during the menstrual cycle) or non-cyclical (related to musculoskeletal causes, medications, or cysts). Pain alone — without a palpable lump or other concerning features — has a very low association with breast cancer.

That said, new breast pain that is persistent, localized to one spot, or accompanied by a lump, skin change, or nipple discharge should be evaluated. Your doctor may recommend a mammogram or ultrasound to rule out an underlying structural cause.

Finding a lump is understandably alarming, but the large majority of palpable breast lumps — especially in women under 40 — are benign. Common causes include cysts, fibroadenomas, and areas of normal but prominent fibrocystic tissue.

The right first step is to contact your doctor promptly so an examination can be arranged. Depending on your age and the characteristics of the lump, imaging will likely be ordered — typically ultrasound for women under 30 and a combination of diagnostic mammogram and ultrasound for women 30 and older. Do not wait to see if it resolves on its own. Early evaluation gives you answers and peace of mind.

Screening guidelines vary by organization, which can be confusing. The American College of Radiology (ACR) and Society of Breast Imaging (SBI) recommend annual mammography starting at age 40 for average-risk women. The U.S. Preventive Services Task Force (USPSTF) updated its 2024 guidelines to recommend biennial (every 2 years) screening starting at age 40, down from their previous recommendation of 50.

Women at higher-than-average risk — due to a strong family history, known genetic mutation (BRCA1/2), or prior chest radiation — may be advised to begin screening earlier and to include annual breast MRI alongside mammography. The best starting point is a conversation with your doctor about your personal risk level so a screening plan can be tailored to you.